Clinical Trial

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study aims to assess the safety and tolerability of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer, and determine the recommended Phase II dose (RP2D); To evaluate of the efficacy of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer based on Prostate-Specific Antigen (PSA) response rate.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-22
Trial Details
NCT Number NCT07407283
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Prostate Cancer
Enrollment 100 participants
Start Date 2026-04-08
Primary Completion 2027-11 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-21